GE HealthCare Technologies (NASDAQ:GEHC) Announces Earnings Results, Beats Estimates By $0.14 EPS

Key Points

• GE HealthCare beat quarterly estimates: Adjusted EPS came in at $1.34 versus the $1.20 consensus, while revenue rose 7.2% year over year to $5.51 billion, exceeding expectations.
• Management raised its full-year 2026 guidance to approximately 4% organic revenue growth, a 15.5%–15.7% adjusted EBIT margin, adjusted EPS of $4.95–$5.05, and free cash flow above $1.6 billion.
• Pharmaceutical Diagnostics and Patient Care Solutions delivered strong growth, and backlog reached $23.7 billion; however, investors continue to monitor tariffs, inflation, supply-chain costs, and leadership changes within Patient Care Solutions.

GE HealthCare Technologies (NASDAQ:GEHC - Get Free Report) issued its earnings results on Wednesday. The company reported $1.34 EPS for the quarter, topping the consensus estimate of $1.20 by $0.14, FiscalAI reports. The company had revenue of $5.51 billion during the quarter, compared to the consensus estimate of $5.35 billion. The firm's revenue for the quarter was up 7.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.07 EPS.

Here are the key takeaways from GE HealthCare Technologies' conference call:

• GE HealthCare raised its full-year 2026 guidance, now expecting approximately 4% organic revenue growth, 15.5%–15.7% adjusted EBIT margin, adjusted EPS of $4.95–$5.05, and free cash flow above $1.6 billion.
• Third-quarter results exceeded expectations, with organic revenue up 6.2%, adjusted EBIT margin expanding 180 basis points to 16.6%, adjusted EPS rising 25.1% to $1.34, and free cash flow increasing to $793 million.
• Pharmaceutical Diagnostics delivered 13.8% organic growth, while Flyrcado adoption continued to build; management remains confident in its goal of reaching a $500 million annualized Flyrcado revenue run rate exiting 2028. The planned SOFIE Biosciences acquisition is intended to strengthen U.S. radiopharmaceutical distribution, manufacturing control, and the precision-medicine pipeline.
• Patient Care Solutions improved sharply, with organic revenue up 8.8% and margin expanding 480 basis points, but fourth-quarter growth will be muted by a difficult comparison related to a prior-year product-hold release. PCS leadership is changing, and GE HealthCare is still evaluating strategic options for the business, although management said the review timeline is unaffected.
• Management characterized capital-equipment demand and the imaging pipeline as resilient, with backlog up 12% year over year to $23.7 billion, but acknowledged ongoing risks from tariffs, inflation, oil prices, and elevated memory-chip costs. Multi-year supplier agreements are expected to improve component availability and reduce supply-chain volatility into 2027.

GE HealthCare Technologies Trading Up 7.8%

Shares of GEHC stock traded up $5.54 on Wednesday, reaching $76.65. 4,081,761 shares of the company's stock were exchanged, compared to its average volume of 4,212,754. GE HealthCare Technologies has a 52 week low of $58.75 and a 52 week high of $89.77. The stock has a market capitalization of $34.62 billion, a PE ratio of 17.58 and a beta of 0.73. The company's fifty day simple moving average is $68.30 and its 200 day simple moving average is $70.23.

GE HealthCare Technologies Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 13th. Stockholders of record on Friday, October 23rd will be paid a dividend of $0.04 per share. This is a positive change from GE HealthCare Technologies's previous quarterly dividend of $0.0350. This represents a $0.16 dividend on an annualized basis and a dividend yield of 0.2%. The ex-dividend date of this dividend is Friday, October 23rd. GE HealthCare Technologies's payout ratio is currently 3.67%.

Key Stories Impacting GE HealthCare Technologies

Here are the key news stories impacting GE HealthCare Technologies this week:

• Positive Sentiment: GEHC reported third-quarter adjusted earnings of $1.34 per share, above the roughly $1.20–$1.21 analyst consensus and up from $1.07 a year earlier. Revenue rose 7.2% year over year to $5.51 billion, exceeding expectations of approximately $5.35 billion. GE HealthCare Technologies Q3 Earnings and Revenues Beat Estimates
• Positive Sentiment: Management cited strong top-line growth, margin expansion across all segments, robust EPS growth and continued customer adoption of new products. The company also raised its fiscal 2026 outlook, strengthening expectations for continued earnings growth. GE HealthCare Reports Third Quarter 2026 Financial Results
• Positive Sentiment: The results suggest that demand for imaging equipment and GEHC’s backlog are helping offset concerns about uneven demand and operational pressures, supporting the stock’s upward move. GE HealthCare Q3 2026 Sales Beat Estimates
• Neutral Sentiment: Jeannette Bankes, president and CEO of Patient Care Solutions, will leave GE HealthCare to become CEO of another company. The departure creates some leadership-transition risk, although it does not change the company’s reported quarterly performance. GE HealthCare Announces Leadership Change
• Negative Sentiment: Prior earnings previews had highlighted Patient Care Solutions weakness, inflation and supply-chain challenges as potential risks to margins. The stronger quarter appears to have reduced those immediate concerns, but they remain factors investors will monitor.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. BTIG Research cut their price target on shares of GE HealthCare Technologies from $79.00 to $75.00 and set a "buy" rating for the company in a research note on Monday, October 12th. Evercore restated an "outperform" rating and issued a $84.00 price objective on shares of GE HealthCare Technologies in a report on Thursday, July 30th. Wolfe Research initiated coverage on GE HealthCare Technologies in a research note on Tuesday, October 20th. They issued a "peer perform" rating for the company. Barclays raised GE HealthCare Technologies to a "strong-buy" rating in a research report on Wednesday, October 7th. Finally, Piper Sandler reaffirmed a "buy" rating on shares of GE HealthCare Technologies in a report on Wednesday, July 29th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and eleven have assigned a Hold rating to the company. According to data from MarketBeat.com, GE HealthCare Technologies has a consensus rating of "Moderate Buy" and an average target price of $78.35.

GE HealthCare Technologies Company Profile

GE HealthCare Technologies Inc is a global medical technology company that develops and provides products, services and digital solutions for healthcare providers. Its offerings are designed to support the diagnosis, treatment and monitoring of patients across hospitals, outpatient facilities, imaging centers and other care settings.

The company's portfolio includes medical imaging systems such as computed tomography, magnetic resonance imaging, molecular imaging, surgical imaging and X-ray equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.